Biovaxys Technology Corporation (QB) (BVAXF) 銘柄情報

Alot more DD over on Stocktwits

Alot of volume today, 1.8mm shares traded.

U.S. Patent granted for the DPX Delivery Platform !

https://www.otcmarkets.com/stock/BVAXF/news/Biovaxys-Signs-Binding-Letter-of-Intent-to-Develop-DPX-Based-Vaccines-for-Life-Threatening-Food-Allergies?id=448207

Great article. Very detailed.

https://www.medicalgold.ca/posts/biovaxys-bargain-bonanza-seizing-a-biotech-treasure-trove-from-imvs-ashes

Booom 😎

VANCOUVER, BC, Feb. 13, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that it has executed the definitive Asset Purchase Agreement dated February 11th, 2024 to acquire the entire portfolio of discovery, preclinical and clinical development stage assets in oncology, infectious disease, antigen desensitization, and other immunological fields based on the DPX™ immune educating platform technology, developed by Canadian biotechnology company, IMV Inc., Immunovaccine Technologies Inc., and IMV USA ("IMV"). BioVaxys acquired the extensive technology portfolio from HIMV, LLC, an acquisition vehicle formed by Horizon Technology Finance Corporation (NASDAQ: HRZN) and IMV's other secured creditors for the purpose of acquiring IMV's intellectual property through a secured party credit bid in the proceedings commenced in Canada by IMV under the Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended (the "CCAA")
Horizon Technology Finance Corporation, an affiliate of Monroe Capital, is a leading specialty finance company that provides capital in the form of secured loans to companies in the technology, life science, healthcare information and services, and sustainability industries. Horizon is headquartered in Farmington, Connecticut, with a regional office in Pleasanton, California, and investment professionals located throughout the U.S.

Key transaction elements include a USD$750,000 upfront cash payment, various clinical development and regulatory milestone payments, a 15% share in license revenues, and a 6% gross sales royalty on product sales (such future gross sales royalties cancellable and extinguishable upon a one-time payment of USD$25,000,000 in cash) and shares of BioVaxys common stock with a deemed value of US$250,000, calculated at a price per share equal to the volume-weighted average price of the common shares during the 20 trading day period immediately prior to closing and will be subject to a hold period of four months and one day. HIMV will also be entitled to appoint an observer to BioVaxys's Board of Directors.

The DPX™ antigen delivery platform acquired by BioVaxys is designed to stimulate a specific, coordinated and persistent anti-tumor immune response, improving the lives of patients with solid or hematological cancers. DPX™ can package a wide range of bioactive molecules in a single formulation, such as multiple nucleic acids/mRNA, proteins, peptides, virus-like particles, innate immune activators, and small molecules, to "feed" them to Dendritic Cells and Antigen Presenting Cells (or "APC's") to stimulate a specific immune response.

The transaction supplements BioVaxys' existing cancer vaccine portfolio with the addition of maveropepimut-S (MVP-S), a DPX™-formulated cancer vaccine that delivers antigenic peptides from survivin, a cancer antigen commonly overexpressed in advanced cancers. MVP-S also delivers an innate immune activator and a universal CD4 T cell helper peptide. These elements foster maturation of antigen presenting cells as well as robust activation of CD8 T cell effector and memory function. Maveropepimut-S was recently in Phase IIB clinical trials for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and is being clinically evaluated in bladder and breast cancer. In prior clinical studies, MVP-S treatment has been well tolerated and has demonstrated favorable clinical outcomes in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. Most recently, data were presented by IMV at the 2023 SGO Annual Meeting on Women's Cancer on a phase 1b/2 multicenter trial designed to evaluate MVP-S combined with intermittent low dose of cyclophosphamide in patients with recurrent, epithelial ovarian, fallopian tube, or peritoneal cancer. Findings showed clinical benefit to patients with recurrent ovarian cancer, regardless of platinum sensitivity or BRCA mutational status.

DPX™ formulations are not limited to cancer immunotherapies. With its unique cargo carrying capacity and non-circulating lipid delivery, there is potential with DPX™ to develop improved mRNA vaccines, multivalent viral vaccines, vaccines for desensitizing immune response for allergies, and immune system diseases. Prior clinical studies by IMV have supported proof of concept and a superior immune response with a DPX-RSV formulation, DPX™-rHA/DPX-FLU influenza vaccine, DPX™-packaged survivin/MAGE-Ag for advanced metastatic bladder cancer, and certain other infectious diseases.

Through the transaction, BioVaxys has acquired 25 distinct families of patents and/or patent applications, with over one hundred related international filings related to maveropepimut-S, DPX™ and its use across a range of immune system-related diseases, associated trademarks, and other intellectual property. The deal also assigns to Biovaxys a royalty-bearing License and Supply Agreement with Wisconsin-based SpayVac for Wildlife Inc., on sales of animal vaccine products using technology acquired by BioVaxys, a milestone payments and royalty bearing license agreement with Pfizer animal health spin-out Zoetis Inc, the world's largest producer of medicine and vaccinations for pets and livestock, for their development and sale of various animal health products using the technology acquired by BioVaxys, and German pharmaceuticals company Merck KGaA for survivin proteins. Survivins are highly expressed in most cancers and are associated with a poor clinical outcome, with the differential expression of survivin in cancer cells compared to normal tissues and its role as a nodal protein in a number of cellular pathways make it a significant target for cancer therapeutics.

Kenneth Kovan, BioVaxys President & Chief Operating Officer stated: "This is an absolutely transformational transaction for Biovaxys that is synergistic with our pre-existing personalized immunotherapeutic vaccines based on our HapTenix© 'neoantigen' tumor cell construct platform, and BVX-0918, our ovarian cancer vaccine candidate. The DPX™ platform and addition of maveropepimut-S to our pre-existing clinical pipeline immediately positions BioVaxys as a major player in ovarian cancer, and expands our pipeline to include advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL), bladder and breast cancer." Kovan added, "We see tremendous commercial potential with the DPX™ platform, which was a major driver of the transaction. The range of antigens that can be packaged and the cargo capacity of DPX™ present the opportunity for BioVaxys to monetize multiple development partnerships such as in the multi-valent and mRNA vaccine fields, expand our own immunotherapeutric pipeline, and establish what we believe will be an almost perpetual string of new BioVaxys IP derived from novel DPX™ formulations. We envision DPX™ enabling new immunotherapeutics not just from BioVaxys, but from a number of other companies via business development partnerships"

James Passin, Biovaxys CEO, stated: "We are honored to continue to advance the outstanding scientific work completed by the former IMV Inc. The overwhelming support that we have received from our investors for this transaction reinforces our conviction that the antigen-packaging and presenting technology that we have acquired will position BioVaxys as a potential world leader in cancer immunotherapy with further growth potential in other significant verticals including allergy desensitization and mRNA."

It is anticipated that the transaction will fully close within ten days.

Halted Pending News 😎

$BVAXF
https://x.com/hannahadad8890/status/1742152691512430760?s=61

$BVAXF acquisition news early in 24 !

$BVAXF
https://x.com/hannahadad8890/status/1741077585117810737?s=61

$BVAXF
https://x.com/hannahadad8890/status/1740871340679213489?s=61

https://twitter.com/spactraderintra/status/1579856532732534784?s=61&t=f7JpLILgxJSFnxUvs3tzCA

For news and updates follow @biovaxys

This company spent almost 13 months behind the scenes working and are now starting to drop bombs from the fruits of their labor

Keeping my eyes on this one

$BVAXF has a monster lineup with an exciting timeline. Like I said I hope to see this baby go to $8 in a period of 5 years. Call me crazy…. But do some dd every year I get more and more excited.

$BVAXF Continues to trade green in a red market..and what is telling to me is the upswing in volume..twice the 10 day average and it’s only lunchtime..got me thinking smart traders are buying as the rest of the market is selling..let that sink in..

Most recent PRs read here. Alot of DD coming in this weekend and still so much to unravel

https://twitter.com/falcon_otc/status/1579416395343097862?s=61&t=-3A4lkbCGVcWz6lqA94JZw

MEGA Research Collaboration w/ Ohio State University to develop a universal vaccine, BVX-1021 to treat SARS1 and other sarbecoviruses.
77M Share Micro Floater
$300,000 Debt Settlement
$18M Market Cap

$BVAXF/ $BIOV @biovaxys
Clinical-stage biopharma founded in 2018 developing antiviral & anticancer vaccine platforms. SARS-CoV-2 and late-stage ovarian cancer vaccine.

? Over $100M in R&D investment by Avax
? Established clinical study design, manufacturing & distribution protocols
? Ovarian Cancer entering stage 3
?Improving on protein haptenization and vaccine develpments by Dr Berd

#otc #biopharma #pharma #fintech

$BVAXF/ $BIOV

Average time to complete all 3 phases of clinical trials is around 8-10 years.

@biovaxys has already reached Phase 3 with Cervial Lesionsand other 3 products are done with PRECLINICAL TESTING in less than 5 years!!

#otc #fintech #biopharma

$BVAXF A 37 percent move higher on a very red market day grabbed my attention here.. as the chart closed above me resistance line..setting up for a very interesting week ahead..just added to my watchlist..

https://stockcharts.com/c-sc/sc?s=BVAXF&p=D&b=5&g=0&i=0&r=1665228644267

BVAXF $$$$ SOMETHING BIG IS COOKING...EXPLODING HARD !!!.

It’s not dead

BVAXF...why did this die? no interest anymore from anyone?

Absolutely

Attention #OTC traders looking for a potentially epic play!
We have just released an article featuring a newly discovered gem known as $BVAXF and we think you will like what you see!
This ticker could pack the punch it takes to be hugely successful in OTC

https://truthfultrading.com/bvaxf-partners-with-6-billion-dollar-company/

Well hello sir

https://finance.yahoo.com/news/fda-provides-necessary-guidance-biovaxys-135000949.html

This will blow by $1 in no time.

Mu mu... mu variant.

We’ve got a runner in progress

News out today

https://twitter.com/biovaxys/status/1435217026717528068?s=21

$BVAXF Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans

https://www.prnewswire.com/news-releases/clinical-trial-affirms-covidth-diagnostic-approach-to-screen-for-t-cell-mediated-immune-response-to-sars-cov-2-is-safe-and-effective-in-humans-301346721.html

LMNGF changed to BVAXF:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

Interesting discussion on_developing pills to_treat pandemic viruses
https://www.statnews.com/2021/04/09/scientists-work-toward-an-elusive-dream-a-simple-pill-to-treat-covid-19/

I wonder if this oral delivery approach (as opposed to injections) is something we are currently looking into?

The Doctor

Get_yer' program!_Get yer'_program! Can't_tell your_variants without a_program
https://www.axios.com/coronavirus-variants-vaccines-c27dd1d5-6531-4c67-80c0-310705d6ff45.html

The Doctor

Sanofi_setting up_shop in Toronto... well_isn't that_nice
https://endpts.com/looking-to-prepare-for-the-next-flu-pandemic-sanofi-drops-700m-into-new-toronto-facility-for-fluzone-production/

The Doctor

It_would appear_the FDA_is inviting_us into_the Sacred_EUA Inner_Sanctum
https://www.stockwatch.com/News/Item/Z-C!BIOV-3056407/C/BIOV

The Doctor

This is heading for HGE*N type move, severely undervalued for COVID and Ovarian cancer. Double digits dollars this time next year.

BioVaxys_Enters Major_Bioproduction Agreement_With Wuxi Biologics
(Hong Kong) Ltd. To Synthesize Proteins For Its SARS-CoV-2 Vaccine And COVID-T™ Immunodiagnostic Programs
https://www.stockwatch.com/News/Item/Z-C!BIOV-3047495/C/BIOV

and Biovaxys signs production deal with WuXi for proteins

I do believe I am going to order a new car for myself later this week... I hope I can afford a new more-attractive sleek younger girlfriend also.

The Doctor

Paris_heads toward_new lockdown_as COVID_patients fill_hospital ICUs
https://www.marketwatch.com/story/paris-heads-toward-new-lockdown-as-covid-patients-fill-hospital-icus-01615743079

This is not good. If Spain and/or Portugal next announces a new lockdown on Monday or Tuesday then the EU is in deep shit.

The Doctor

COVID variants are a "whole new ballgame"
https://www.axios.com/michael-osterholm-coronavirus-variants-a15eaf2c-88fe-42b4-935b-7a2264a237a1.html

We need to closely watch Italy now. https://www.cnn.com/2021/03/13/europe/italy-coronavirus-national-lockdown-intl/index.html

If Italy explodes under the strain of this new Covid variant then there is going to be a huge push for a new more-powerful more-comprehensive vaccine and that is where BioVaxyz easily steps up to the call.

The Doctor

BioVaxys_expanding technology_platform to_address emerging SARS-CoV-2 variants
https://finance.yahoo.com/news/biovaxys-expanding-technology-platform-address-130000326.html
Hmmmm I can almost taste that new vaccine coming, I do believe it tastes like warm macadamia cookies (eg Subway cookies) fresh out of the oven... one my favorites.

The Doctor

We've_grown so_much bigger/strategic now_that we_are getting_properly "advised"
https://finance.yahoo.com/news/biovaxys-announces-appointment-corporate-advisor-130000550.html

And I certainly have always especially enjoy it most when us regular shareholders get a nice strong Big Daddy Warbucks type advisor.

The Doctor

UK_virus variant_on course_to sweep world... bloody! Oh_my.
Covid-19: Kent virus variant 'on course to sweep world'

and from Germany
Germany's Merkel Warns Coronavirus Variants Could 'Destroy' Gains Against Pandemic

J&J_CEO: Annual COVID-19 vaccine_shots may_be necessary_for a_few years
https://www.axios.com/covid-vaccines-annual-johnson-johnson-9a3521e0-e1a7-48de-899c-92b1f54251af.html

Dear Johnson & Johnson CEO Alex Gorsky, annnddddd what exactly is the bad news here? Three years would be good... 4-7 years even better.

In this situation it's like my girlfriend always says... "the longer the better".

The Doctor

Dear_Li3/LIEG Friends, LMNGF_is probably_going to_rocket after_HALT is_lifted

Jeremy resigns from Biovaxys
https://www.stockwatch.com/News/Item?bid=Z-C:BIOV-3028521&symbol=BIOV®ion=C

PROCARE INVESTS USD$900,000 TO BIOVAXYS' CANCER & COVID VACCINE BREAKTHROUGH
https://www.stockwatch.com/News/Item?bid=Z-C:BIOV-3029072&symbol=BIOV®ion=C

Trading HALT
https://www.stockwatch.com/News/Item?bid=Z-C:BIOV-3029084&symbol=BIOV®ion=C

The Doctor

The_New Race_for Super_Duper Vaccine_is definitely_on now
UK coronavirus variant spreading 'rapidly' through US, study finds

The Doctor

The_Grand Overall_Macro "Big Picture" on_THE vaccine... at least,_for this_week
coming up
https://www.axios.com/coronavirus-vaccines-safe-effective-science-immunity-aaa8b39e-1840-482a-a099-050c31529d1c.html
It looks like the researcher that can zero in on and solve the Covid-19 South African variant first will be the next billion(s) dollar golden boy.

The Doctor

This_whole Covid-19 plague_gets more_complicated by_the day
https://news.yahoo.com/vietnam-confirms-latest-virus-outbreak-063830480.html
Just keeping up with all the new variants is a huge effort.
Now poor Vietnam is deep(er) in the mix.

The Doctor

Russia's Sputnik_V vaccine_is highly_effective, study_finds
https://www.axios.com/russia-sputnik-coronavirus-vaccine-covid-9804ed4b-3b3d-4a96-9fdc-7622098fe488.html

North American Covid-19 vaccine researchers (eg us) are going to have to kick it up another two gears now in order to get back out in front of this race for a better more-efficient easier-to-store and easier-to-use two-doses-in-one-vial longer-shelf-life shot.

The Doctor